The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2026 | Targeting macrophages to prevent neuroendocrine transformation in lung cancer
Triparna Sen, PhD, The Ohio State University, Columbus, OH, comments on the importance of understanding the immune microenvironment’s contribution to neuroendocrine transformation in small cell lung cancer, highlighting the role of monocyte-derived macrophages in this process. Targeting this class of macrophages could lead to innovative therapeutic strategies, such as using lipid nanoparticles, and combinatorial approaches with current immunotherapies, like immune checkpoint blockade or T-cell engagers, as well as EGFR TKIs. This interview took place at the IASLC 2026 World Conference on Lung Cancer congress in Seoul, Republic of Korea.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
